It is found that removing an enzyme from mice with symptoms of Alzheimer’s disease leads to a 90 percent reduction in the compounds responsible for formation of the plaques linked to this dreaded disease.
“That is the most dramatic reduction in this compound reported to date”claims a research published by Science Daily(Sep. 5, 2012).
“The compounds are amyloid beta, or A-beta peptides; peptides are proteins, but are shorter in length. When A-beta peptides accumulate in excessive amounts in the brain, they can form plaques, which are a hallmark of Alzheimer’s disease.
These mice are models for the most aggressive form of Alzheimer’s disease and produce the highest amount of A-beta peptides. This 90 percent reduction is the biggest drop in A-beta levels that has been reported so far by treating animal models with drugs or genetic manipulations,” said Sung Ok Yoon, associate professor of molecular & cellular biochemistry at Ohio State University and lead author of the study.
The same article notes that Alzheimer’s disease affects more than 5 million Americans, and its cause remains unknown. “Although scientists have not yet determined whether A-beta peptides present in plaques cause Alzheimer’s disease or form as a consequence of the disease, the presence of the plaques is linked to progressive cognitive decline”,it says.
Further this study claims this:“Yoon and colleagues deleted jnk3 genetically from Alzheimer’s disease model mice carrying the mutations that are found among early-onset Alzheimer’s disease patients. In six months, the deletion of the enzyme had lowered A-beta peptide production by 90 percent, which persisted over time, with a 70 percent reduction seen at 12 months in these mice.”